Mortality and morbidity of status epilepticus over the long term.

Status epilepticus is associated with high mortality and morbidity, both in the acute phase and over the long term. However, the long-term outcome of SE is not well studied, and there is no consensus on how to measure and predict it. Moreover, the factors that influence the long-term outcome of SE are complex and multifactorial, and may vary depending on the patient's characteristics, the SE etiology and type, and the treatment and complications. The aim of this article is to review the current literature on the mortality and morbidity of SE over the long term and to discuss the challenges and perspectives for future research. Proceedings of the 9th London-Innsbruck Colloquium on Status Epilepticus and acute seizures.

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: L Kämppi reports speakers’ honoraria from UCB, Angelini Pharma and Sobi and congress/travel support from UCB and Angelini Pharma and Personal grants from Academy of Finland, Finnish Cultural Foundation and HUS Neurocenter. A Kämppi declares no competing interests. A. Strzelczyk reports personal fees and grants from Angelini Pharma, Biocodex, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals, Takeda, UCB Pharma, and UNEEG Medical.